

Antonella Poloni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4417004/publications.pdf>

Version: 2024-02-01

96
papers

2,876
citations

159525

30
h-index

182361

51
g-index

99
all docs

99
docs citations

99
times ranked

4102
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Translational Read-throughâ€“Inducing Drugs as a Therapeutic Option for Shwachman-Diamond Syndrome. <i>Biomedicines</i> , 2022, 10, 886.	1.4	7
2	Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience. <i>Leukemia</i> , 2022, 36, 1947-1950.	3.3	9
3	The exosomal surface phenotype and inflammaâ€“miR cargo correlate with MDS diagnosis. <i>British Journal of Haematology</i> , 2021, 192, e4-e7.	1.2	4
4	Apoptotic mechanism activated by blue light and cisplatinum in cutaneous squamous cell carcinoma cells. <i>International Journal of Molecular Medicine</i> , 2021, 47, .	1.8	7
5	Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. <i>Cancer</i> , 2021, 127, 2015-2024.	2.0	2
6	Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome?. <i>Frontiers in Oncology</i> , 2020, 10, 595838.	1.3	1
7	SARSâ€“CoVâ€“2â€“in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. <i>HemaSphere</i> , 2020, 4, e483.	1.2	7
8	Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). <i>Bone Marrow Transplantation</i> , 2020, 55, 2077-2086.	1.3	5
9	A novel method to evaluate prethawing viability of cryopreserved CD34 + hematopoietic stem cells for autologous transplantation. <i>Transfusion</i> , 2020, 60, 1529-1535.	0.8	7
10	Bone marrow adipose tissue is a unique adipose subtype with distinct roles in glucose homeostasis. <i>Nature Communications</i> , 2020, 11, 3097.	5.8	98
11	Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study. <i>Scientific Reports</i> , 2020, 10, 9156.	1.6	9
12	mTOR and STAT3 Pathway Hyper-Activation is Associated with Elevated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment. <i>Cancers</i> , 2020, 12, 597.	1.7	7
13	Reporting Guidelines, Review of Methodological Standards, and Challenges Toward Harmonization in Bone Marrow Adiposity Research. Report of the Methodologies Working Group of the International Bone Marrow Adiposity Society. <i>Frontiers in Endocrinology</i> , 2020, 11, 65.	1.5	53
14	The Time Has Come for Targeted Therapies for AML: Lights and Shadows. <i>Oncology and Therapy</i> , 2020, 8, 13-32.	1.0	32
15	Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-Î² and p-SMAD Pathway. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 823-834.	2.0	30
16	Feasibility and Outcome of a Phase-III Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment. <i>Advances in Therapy</i> , 2020, 37, 2288-2302.	1.3	1
17	History and Scientific Production of <i>Clinica Medica</i> and <i>Clinica Ematologica</i> in Ancona. , 2020, , 1-11.		0
18	Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study. <i>Haematologica</i> , 2019, 104, e4-e8.	1.7	9

#	ARTICLE	IF	CITATIONS
19	Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis. <i>Cancer Medicine</i> , 2019, 8, 7567-7576.	1.3	5
20	Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. <i>Blood Reviews</i> , 2019, 34, 16-25.	2.8	15
21	Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial. <i>Blood</i> , 2019, 134, 3000-3000.	0.6	7
22	Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes. <i>Cell Transplantation</i> , 2018, 27, 754-764.	1.2	36
23	Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency. <i>European Journal of Haematology</i> , 2018, 101, 78-85.	1.1	5
24	Adipocytes properties and crosstalk with immune system in obesity-related inflammation. <i>Journal of Cellular Physiology</i> , 2018, 233, 88-97.	2.0	181
25	A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. <i>Leukemia</i> , 2018, 32, 413-418.	3.3	58
26	Bone marrow adipocytes support hematopoietic stem cell survival. <i>Journal of Cellular Physiology</i> , 2018, 233, 1500-1511.	2.0	88
27	Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 267-275.	2.0	33
28	Bone Marrow "Yellow" and "Red" Adipocytes: Good or Bad Cells?. <i>Current Molecular Biology Reports</i> , 2018, 4, 117-122.	0.8	5
29	Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. <i>Lancet Haematology</i> , 2017, 4, e127-e136.	2.2	132
30	Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. <i>British Journal of Haematology</i> , 2017, 177, 741-750.	1.2	23
31	Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. <i>Annals of Oncology</i> , 2017, 28, 1547-1553.	0.6	46
32	Human White Adipocytes Convert Into "Rainbow" Adipocytes In Vitro. <i>Journal of Cellular Physiology</i> , 2017, 232, 2887-2899.	2.0	28
33	ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems. <i>American Journal of Hematology</i> , 2017, 92, 1037-1046.	2.0	20
34	DNA demethylating therapy reverts mesenchymal stromal cells derived from high risk myelodysplastic patients to a normal phenotype. <i>British Journal of Haematology</i> , 2017, 177, 818-822.	1.2	12
35	The Exaggerated Collagen Expression in Gvhd-Fibroblasts Is Effectively Inhibited By Therapeutic Concentration of Nilotinib. <i>Blood</i> , 2016, 128, 4597-4597.	0.6	0
36	Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence. <i>Cancer Medicine</i> , 2015, 4, 1789-1797.	1.3	18

#	ARTICLE	IF	CITATIONS
37	Glial-Like Differentiation Potential of Human Mature Adipocytes. <i>Journal of Molecular Neuroscience</i> , 2015, 55, 91-98.	1.1	13
38	Plasticity of human dedifferentiated adipocytes toward endothelial cells. <i>Experimental Hematology</i> , 2015, 43, 137-146.	0.2	27
39	Biosafety evidence for human dedifferentiated adipocytes. <i>Journal of Cellular Physiology</i> , 2015, 230, 1525-1533.	2.0	10
40	Interaction between human mature adipocytes and lymphocytes induces T-cell proliferation. <i>Cytotherapy</i> , 2015, 17, 1292-1301.	0.3	20
41	Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. <i>Journal of Clinical Investigation</i> , 2015, 125, 1857-1872.	3.9	151
42	A Combination of Lenalidomide and Rituximab (ReRi) As Salvage Therapy in Elderly Patients Affected By Diffuse Large B Cells (DLBCL) Lymphoma Relapsed and Refractory. <i>Blood</i> , 2015, 126, 5109-5109.	0.6	4
43	Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial. <i>Blood</i> , 2015, 126, 91-91.	0.6	7
44	Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1657-1660.	0.6	5
45	Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes. <i>Leukemia</i> , 2014, 28, 2241-2244.	3.3	13
46	Mobilization-Driven Postconsolidation Therapy in Elderly Patients with Acute Myeloid Leukemia: Feasibility and Efficacy of Autologous Stem Cell Transplantation versus Low-Dose Gemtuzumab Ozogamicin. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1399-1406.	2.0	10
47	Azacitidine Treatment in High Risk Myelodysplastic Patients in Complete Haematological Remission Reverts Mesenchymal Stem Cells to a Normal Phenotype. <i>Blood</i> , 2014, 124, 1904-1904.	0.6	2
48	Molecular and Functional Characterization of Human Adipocytes. <i>Stem Cells and Cancer Stem Cells</i> , 2014, , 231-240.	0.1	0
49	Molecular and Functional Characterization of Human Adipocytes. <i>Tumors of the Central Nervous System</i> , 2014, , 51-60.	0.1	0
50	Molecular Determinants of Decitabine Response in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2014, 124, 4644-4644.	0.6	0
51	Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. <i>Annals of Hematology</i> , 2013, 92, 25-32.	0.8	23
52	Valproic acid for the treatment of low-risk myelodysplastic syndromes: A case report and a review of the literature. <i>Leukemia Research Reports</i> , 2013, 2, 44-46.	0.2	0
53	Molecular and functional characterization of human bone marrow adipocytes. <i>Experimental Hematology</i> , 2013, 41, 558-566.e2.	0.2	74
54	Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. <i>Leukemia and Lymphoma</i> , 2013, 54, 2458-2465.	0.6	29

#	ARTICLE	IF	CITATIONS
55	Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome. <i>Leukemia Research</i> , 2013, 37, 1538-1544.	0.4	16
56	Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2013, 90, 345-348.	1.1	37
57	Prognostic role of immunohistochemical analysis of 5 mc in myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2013, 91, 219-227.	1.1	16
58	Low FasL levels promote proliferation of human bone marrow-derived mesenchymal stem cells, higher levels inhibit their differentiation into adipocytes. <i>Cell Death and Disease</i> , 2013, 4, e594-e594.	2.7	23
59	Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. <i>Blood</i> , 2013, 122, 4111-4118.	0.6	90
60	Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?. <i>Blood</i> , 2013, 122, 2286-2288.	0.6	67
61	A Real Life Survey On Erythropoietin Alpha Treatment In a Cohort Of 1049 Low Risk MDS Patients: An Italian MDS Registry Study. <i>Blood</i> , 2013, 122, 745-745.	0.6	1
62	Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGA. <i>Oncologist</i> , 2012, 17, 663-672.	1.9	52
63	Human Differentiated Adipocytes Show Similar Properties to Bone Marrow-Derived Mesenchymal Stem Cells. <i>Stem Cells</i> , 2012, 30, 965-974.	1.4	119
64	Human AB serum for generation of mesenchymal stem cells from human chorionic villi: comparison with other source and other media including platelet lysate. <i>Cell Proliferation</i> , 2012, 45, 66-75.	2.4	35
65	High Predictive Value of the Revised International Prognostic Scoring System (IPSS-R): An External Analysis of 646 Patients From a Multiregional Italian MDS Registry. <i>Blood</i> , 2012, 120, 1702-1702.	0.6	3
66	Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the European Hematology Association). <i>Journal of Clinical Oncology</i> , 2012, 30, 1080-1080.	0.6	10
67	Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS). <i>Blood</i> , 2012, 120, 923-923.	0.6	10
68	Quality of life and physicians' perception in myelodysplastic syndromes. <i>American Journal of Blood Research</i> , 2012, 2, 136-47.	0.6	37
69	Gene expression profile of cytokines in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with reduced conditioning. <i>Cytokine</i> , 2011, 53, 376-383.	1.4	14
70	Human Mesenchymal Stem Cells from Chorionic Villi and Amniotic Fluid are not Susceptible to Transformation after Extensive in Vitro Expansion. <i>Cell Transplantation</i> , 2011, 20, 643-654.	1.2	71
71	Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1 risk myelodysplastic syndromes with chromosome 5q deletion. <i>European Journal of Haematology</i> , 2010, 85, 231-235.	1.1	25
72	Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study. <i>British Journal of Haematology</i> , 2010, 150, 119-120.	1.2	7

#	ARTICLE	IF	CITATIONS
73	P077 Adaptation and changes in quality of life in patients with myelodysplastic syndrome. Leukemia Research, 2009, 33, S103.	0.4	0
74	P110 Lenalidomide in low and int-1 risk MDS with del5q: efficacy and quality of life. Leukemia Research, 2009, 33, S123.	0.4	0
75	P112 Gene expression patterns in MDS with del5q before and during lenalidomide treatment. Leukemia Research, 2009, 33, S124.	0.4	0
76	Selection of CD271+ cells and human AB serum allows a Large expansion of mesenchymal stromal cells from human bone marrow. Cytotherapy, 2009, 11, 153-162.	0.3	66
77	Lenalidomide for the Treatment of Low- and Int-1-Risk MDS with Del(5q): Efficacy and Quality of Life Study.. Blood, 2009, 114, 2763-2763.	0.6	1
78	Characterization and expansion of mesenchymal progenitor cells from first-trimester chorionic villi of human placenta. Cytotherapy, 2008, 10, 690-697.	0.3	80
79	Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood, 2007, 110, 237-241.	0.6	212
80	A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients. Experimental Hematology, 2007, 35, 1074-1082.	0.2	7
81	Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood, 2006, 108, 2159-2164.	0.6	101
82	Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. Leukemia, 2006, 20, 329-335.	3.3	42
83	A New Schedule of CHOP/Rituximab Plus Granulocyte-Macrophage Colony-Stimulating Factor Is an Effective Rescue for Patients with Aggressive Lymphoma Failing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 627-636.	2.0	21
84	Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. Bone Marrow Transplantation, 2004, 34, 693-702.	1.3	11
85	Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. European Journal of Haematology, 2004, 72, 10-17.	1.1	43
86	High Dose Chemotherapy (HD CHT) Followed by Autologous PBPC Transplant in Elderly ANLL Patients.. Blood, 2004, 104, 881-881.	0.6	13
87	Long-term hematologic reconstitution after autologous peripheral blood progenitor cell transplantation: a comparison between controlled-rate freezing and uncontrolled-rate freezing at 80°C. Transfusion, 2003, 43, 42-49.	0.8	35
88	Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience. Bone Marrow Transplantation, 2001, 27, 1189-1195.	1.3	33
89	Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. British Journal of Haematology, 2000, 110, 300-307.	1.2	55
90	Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard. Experimental Hematology, 1999, 27, 1548-1556.	0.2	13

#	ARTICLE	IF	CITATIONS
91	Flt 3 ligand, MGDF, Epo and G-CSF enhance ex vivo expansion of hematopoietic cell compartments in the presence of SCF, IL-3 and IL-6. Bone Marrow Transplantation, 1998, 21, 759-767.	1.3	44
92	Comparison of CD34+ bone marrow cells purified by immunomagnetic and immunoadsorption cell separation techniques. Bone Marrow Transplantation, 1998, 21, 933-938.	1.3	16
93	Pharmacologic Bone Marrow Purging: Is There Any Place for Etoposide? In Vitro Comparison with Mafosfamide. Stem Cells and Development, 1997, 6, 137-144.	1.0	6
94	The ex vivo expansion capacity of normal human bone marrow cells is dependent on experimental conditions: role of the cell concentration, serum and CD34+ cell selection in stroma-free cultures. Hematology and Cell Therapy, 1997, 39, 49-58.	0.7	36
95	Optimization of the yield of PBSC for autotransplantation mobilized by high-dose chemotherapy and G-CSF: proposal for a mathematical model. Bone Marrow Transplantation, 1994, 14, 273-8.	1.3	20
96	PBSC Collection after High Dose Chemotherapy Followed by G-CSF in Patients with Malignancies: Analysis of Results regarding Factors Affecting the Yield of Hemopoietic Progenitors. International Journal of Artificial Organs, 1993, 16, 57-63.	0.7	4